RASGRP2

Across TCGA pan-cancer cohorts, RASGRP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RASGRP2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RASGRP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RASGRP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where RASGRP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.786	0.447	.001	41	view →
UCEC	DFS	Median	III,IV	0.494	0.905	.044	8	view →
LUAD	DFS	Quartile	III,IV	0.473	0.993	.040	6	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	5	view →
PDAC	OS	Median	All	0.548	0.305	.013	3	view →
GBM	DFS	Quartile	All	0.270	0.411	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RASGRP2–CCRCC (DFS)

Open the CCRCC breakdown →